TY - JOUR
T1 - Drug interactions of zonisamide with phenytoin and sodium valproate
T2 - serum concentrations and protein binding
AU - Tasaki, Kohsuke
AU - Minami, Taketsugu
AU - Ieiri, Ichiro
AU - Ohtsubo, Kenji
AU - Hirakawa, Yoshihiro
AU - Ueda, Kohji
AU - Higuchi, Shun
N1 - Funding Information:
ACKNOWLEDGEMENTS We wish to thank Dr. K. Tokugawa and Mr. NJ. Halewood for their help in preparing the manuscript. This work was partly supported by a Grant-in-Aid for Scientific Research, 05807066 (T.M.), from the Ministry of Education, Science and Culture, Japan, a Research Grant for Nervous and Mental Disorders, 4A-1 (T.M.), from the Ministry of Health and Welfare, Japan, and a Research Grant (T.M.) from the Japan Epilepsy Research Foundation.
Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 1995
Y1 - 1995
N2 - The influence of co-medication with zonisamide (ZNS) on the serum concentration and protein binding of phenytoin (PHT) and sodium valproate (VPA) was studied in 21 pediatric patients. No significant correlation between the daily ZNS dose, and total serum concentrations, free concentrations or free fractions (FF) of PHT or VPA was observed. The patient study showed that changes in the FF of PHT and VPA were correlated more closely with the serum protein and bilirubin levels than changes in the ZNS dosage. An in vitro study revealed that the addition of ZNS caused decreases in the FF of PHT and VPA. However, these decreases were within the range of measurement error and were negligible. In conclusion, no significant effect of ZNS on the serum concentration or protein binding of PHT or VPA was demonstrated.
AB - The influence of co-medication with zonisamide (ZNS) on the serum concentration and protein binding of phenytoin (PHT) and sodium valproate (VPA) was studied in 21 pediatric patients. No significant correlation between the daily ZNS dose, and total serum concentrations, free concentrations or free fractions (FF) of PHT or VPA was observed. The patient study showed that changes in the FF of PHT and VPA were correlated more closely with the serum protein and bilirubin levels than changes in the ZNS dosage. An in vitro study revealed that the addition of ZNS caused decreases in the FF of PHT and VPA. However, these decreases were within the range of measurement error and were negligible. In conclusion, no significant effect of ZNS on the serum concentration or protein binding of PHT or VPA was demonstrated.
UR - http://www.scopus.com/inward/record.url?scp=0029000568&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029000568&partnerID=8YFLogxK
U2 - 10.1016/0387-7604(95)00032-7
DO - 10.1016/0387-7604(95)00032-7
M3 - Article
C2 - 7573757
AN - SCOPUS:0029000568
VL - 17
SP - 182
EP - 185
JO - Brain and Development
JF - Brain and Development
SN - 0387-7604
IS - 3
ER -